Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 8 Nov 2026
Standard addition

Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial.

Standard kidney-protection therapy remains the best available option for IgA nephropathy, as adding rituximab didn't improve outcomes in this major trial.

This PubMed-indexed study examined rituximab in iga nephropathy: the rita multicenter randomized trial. No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN FUNDING: Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.

What the study was

Study design
Multicenter randomized controlled trial
Population
Human participants or human evidence described in the PubMed abstract
Sample size
106
Category
Treatment Innovation
Maturity
Validated
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation

Why it surfaced

Multicenter randomized controlled trial with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.